DISEASE AND HEALTH: ASTHMA RESILIENCE THROUGH MICRORNA ATTRIBUTES (DHARMA)
DISEASE AND HEALTH: ASTHMA RESILIENCE THROUGH MICRORNA ATTRIBUTES (DHARMA)
批准号:
8997382
负责人:
KELAN G TANTISIRA
金额:
$48.02万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-15 至 2018-06-30
关键词:
AccountingAffectAgeAsthmaBiological MarkersBiologyBloodCellsChildChildhoodChildhood AsthmaCholecalciferolChronic DiseaseClinicalClinical DataDataDevelopmentDiagnosisDiseaseDisease susceptibilityEmergency SituationEpithelial CellsGene ChipsGene ExpressionGenesGoalsHealthHealth Care CostsHealthcareHumanImmuneIncidenceIndividualInflammationInflammatoryInterventionInvestigationJointsLeadLifeLungMeasurementMeasuresMethodsMicroRNAsModelingModificationMolecularMorbidity - disease rateOutcomeParticipantPathogenesisPharmaceutical PreparationsPlayPopulationPredictive ValuePredispositionPreventionPrimary PreventionProcessPrognostic MarkerProtein BiosynthesisRNARecording of previous eventsRecurrenceRepressionResourcesRiskRoleSample SizeSchoolsSerumSignal PathwaySmooth Muscle MyocytesSpecific qualifier valueStatistical ModelsTestingTimeTissuesTranscriptTranslational RepressionUnited StatesValidationVisitVitamin DWheezingabstractingasthmaticasthmatic airwaybasebench to bedsidecell typecirculating microRNAcohortcomputer based statistical methodsdifferential expressionearly childhoodepigenetic regulationgenome-wideimprovedindexinginhibitor/antagonistinsightinterestmRNA Transcript Degradationneoplasticnew therapeutic targetnovelpredictive modelingpreventprognosticprognostic valueprospectiveprotein protein interactionpublic health relevanceresiliencerespiratory smooth muscleresponsetherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Asthma affects over 300 million individuals worldwide. MicroRNAs (miRNAs) are small noncoding ribonucleic acids (RNAs) that regulate protein synthesis by way of gene trans-repression or RNA silencing. A growing number of studies demonstrate that miRNAs control signaling pathways in every cell type and regulate inflammation. Thus, miRNAs likely play a profound role in the pathogenesis of, and susceptibility to, asthma. Early miRNA studies have identified several miRNAs associated with asthma. The presence of miRNAs stably expressed in blood indicates that miRNAs may be used as noninvasive biomarkers of asthma susceptibility and resilience. The major goal of this project is to formulate a predictive biomarker test for asthma incidence and resilience based on circulating miRNAs. To accomplish this, we have specified three coordinated specific aims. The first aim evaluates data from the genome-wide sequencing of miRNAs in the serum of 139 children from Project Viva with a history of recurrent wheezing and determines association with the subsequent asthma susceptibility and resilience four years later. The miRNA markers will then be incorporated into a predictive set of miRNA using a Bayesian network approach. The second aim seeks to prospectively validate the predictive test in an independent population of children with a history of recurrent wheezing participating in the Vitamin D Antenatal Asthma Reduction Trial (VDAART). Serum is currently available from early childhood and asthma incidence outcomes will be measured over the next three years. The Bayesian predictive miRNA models developed in Project Viva will be tested in VDAART and refined if necessary. Longitudinal miRNA measurements will permit direct asthma resilience vs. asthma susceptibility testing to assure that the predictive miRNA remain biologically relevant. Our final aim will be to interrogate
the joint effects of vitamin D, which also has potential biomarker potential for asthma susceptibility, and the measured miRNA on asthma susceptibility and resilience. This will be done via statistical modeling within Project Viva and VDAART, as well as via using miRNA mimics and inhibitors and vitamin D on airway derived smooth muscle and epithelial cells. By examining changes in gene expression, a mechanistic understanding for the observed clinical associations can be garnered. We believe that these findings will uncover the role of miRNAs in asthma susceptibility and resilience and will lead to novel interventions, including miRNA targeting, to predict and alleviate this major health care problem.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DISEASE AND HEALTH: ASTHMA RESILIENCE THROUGH MICRORNA ATTRIBUTES (DHARMA)
-
批准号:9143796
-
项目类别:
-
资助金额:$45.58万
-
财政年份:2015
-
负责人:KELAN G TANTISIRA
-
依托单位:
MICRORNAS IN CIRCULATION: ONTOLOGIES OF ASTHMA SEVERITY AND TREATMENT (MICROCOAST)
-
批准号:8865064
-
项目类别:
-
资助金额:$91.07万
-
财政年份:2015
-
负责人:KELAN G TANTISIRA
-
依托单位:
GENOMICS AND PHARMACOGENOMICS OF SYMPTOMS IN ASTHMA
-
批准号:8517208
-
项目类别:
-
资助金额:$42.3万
-
财政年份:2011
-
负责人:KELAN G TANTISIRA
-
依托单位:
Genomics and Pharmacogenomics of Symptoms in Asthma
-
批准号:10299565
-
项目类别:
-
资助金额:$77.46万
-
财政年份:2011
-
负责人:KELAN G TANTISIRA
-
依托单位:
Genomics and Pharmacogenomics of Symptoms in Asthma
-
批准号:10478254
-
项目类别:
-
资助金额:$71.75万
-
财政年份:2011
-
负责人:KELAN G TANTISIRA
-
依托单位:
GENOMICS AND PHARMACOGENOMICS OF SYMPTOMS IN ASTHMA
-
批准号:8258374
-
项目类别:
-
资助金额:$44.61万
-
财政年份:2011
-
负责人:KELAN G TANTISIRA
-
依托单位:
Genomics and Pharmacogenomics of Symptoms in Asthma
-
批准号:10683190
-
项目类别:
-
资助金额:$70.84万
-
财政年份:2011
-
负责人:KELAN G TANTISIRA
-
依托单位:
GENOMICS AND PHARMACOGENOMICS OF SYMPTOMS IN ASTHMA
-
批准号:8339351
-
项目类别:
-
资助金额:$44.63万
-
财政年份:2011
-
负责人:KELAN G TANTISIRA
-
依托单位:
INTEGRATIVE PHARMACOGENOMICS OF LEUKOTRIENE INHIBITION IN ASTHMA
-
批准号:8243556
-
项目类别:
-
资助金额:$72.51万
-
财政年份:2009
-
负责人:KELAN G TANTISIRA
-
依托单位:
INTEGRATIVE PHARMACOGENOMICS OF LEUKOTRIENE INHIBITION IN ASTHMA
-
批准号:7580679
-
项目类别:
-
资助金额:$74.06万
-
财政年份:2009
-
负责人:KELAN G TANTISIRA
-
依托单位:
INTEGRATIVE PHARMACOGENOMICS OF LEUKOTRIENE INHIBITION IN ASTHMA
-
批准号:8450892
-
项目类别:
-
资助金额:$68.17万
-
财政年份:2009
-
负责人:KELAN G TANTISIRA
-
依托单位:
INTEGRATIVE PHARMACOGENOMICS OF LEUKOTRIENE INHIBITION IN ASTHMA
-
批准号:8051788
-
项目类别:
-
资助金额:$73.09万
-
财政年份:2009
-
负责人:KELAN G TANTISIRA
-
依托单位:
INTEGRATIVE PHARMACOGENOMICS OF LEUKOTRIENE INHIBITION IN ASTHMA
-
批准号:7808860
-
项目类别:
-
资助金额:$73.7万
-
财政年份:2009
-
负责人:KELAN G TANTISIRA
-
依托单位:
Pharmacogenetic Linkage of Corticosteroid Response: Asthma Therapy Implications
-
批准号:7086502
-
项目类别:
-
资助金额:$16.18万
-
财政年份:2006
-
负责人:KELAN G TANTISIRA
-
依托单位:
Pharmacogenetic Linkage of Corticosteroid Response: Asthma Therapy Implications
-
批准号:7489024
-
项目类别:
-
资助金额:$16.18万
-
财政年份:2006
-
负责人:KELAN G TANTISIRA
-
依托单位:
Pharmacogenetic Linkage of Corticosteroid Response: Asthma Therapy Implications
-
批准号:7282081
-
项目类别:
-
资助金额:$16.18万
-
财政年份:2006
-
负责人:KELAN G TANTISIRA
-
依托单位:
Pharmacogenetics of Asthma Treatment
-
批准号:8139116
-
项目类别:
-
资助金额:$195.74万
-
财政年份:2000
-
负责人:KELAN G TANTISIRA
-
依托单位:
Pharmacogenetics of Asthma Treatment
-
批准号:8516556
-
项目类别:
-
资助金额:$186.46万
-
财政年份:2000
-
负责人:KELAN G TANTISIRA
-
依托单位:
Pharmacogenetics of Asthma Treatment
-
批准号:8688300
-
项目类别:
-
资助金额:$191.94万
-
财政年份:2000
-
负责人:KELAN G TANTISIRA
-
依托单位:
Pharmacogenetics of Asthma Treatment
-
批准号:7867594
-
项目类别:
-
资助金额:$199.28万
-
财政年份:2000
-
负责人:KELAN G TANTISIRA
-
依托单位:
海外基金